How to optimize the sequential use of novel therapeutics in metastatic prostate cancer patients? Response should be found in prostate cancer tissue
- 84 Downloads
To date, Food and Drug Administration (FDA) approved abiraterone acetate (AA), enzalutamide (E), and cabazitaxel (Cbz) as new options for patients with castration-resistant prostate cancer (CRPC) whose disease progresses during or after docetaxel (D) treatment. However, little data are available about optimal sequencing for these agents. Recently, Schrader et al.  described the effects of E after AA failure. Their data showed that E is only moderately effective and suggested that cross-resistance between AA and E was a common phenomenon. Conversely, Pezaro et al. demonstrate significant Cbz activity in CRPC progressing after treatment with D and AA or E . In this study, activity on Cbz appeared more modest in the cohort not treated with AA nor E, while higher antitumour activity with Cbz in AA- and E-treated patients was reported. Authors hypothesized that the constitutively activated androgen receptor (AR) splice variants, which generally could result in resistance...
KeywordsProstate Cancer Androgen Receptor Abiraterone Enzalutamide Cabazitaxel
Conflicts of interest